LOS ANGELES, Sept. 18, 2017 -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company will be a sponsor of the XIII European Bifurcation Club (www.bifurc.net) meeting at the Casa Das Artes in Porto, Portugal on Friday, October 13th and Saturday, October 14th, 2017. Dr. Mehran Khorsandi, the Company’s co-founder, chairman and chief medical officer will make a presentation entitled "Bifurcations Made Easy" at the conference.
“Our platform based technology is unlike anything on the market today. We have put extensive patent protection in place and are working with key institutions and KOL’s to advance our program as we move forward to commercialize the technology and pursue regulatory approval,” commented CEO Charles Laverty.
Advanced Bifurcation Systems, through its novel Mother/Daughter (“MD”) platform, has complete coverage for all lesions regardless of branch angle, size, plaque burden or location. This single system addresses both the main and side branch, and is mechanically fail-safe and self-aligning for perfect placement.
Dr. Mehran Khorsandi commented, “We have really worked hard to perfect our technology and believe that when we commercialize our product more interventional cardiologists will be comfortable doing complex bifurcations. Our unique technology enables assembly of a bifurcating stent at the carina, regardless of angles, sizes or plaque burden. We expect that our platform, which has been tested in 10 patients to date, will require limited training, greatly reduce procedure times and improve clinical outcomes.”
About Advanced Birfurcation Systems
Advanced Bifurcation Systems (“ABS”) is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure. The Company’s groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent. For more information, go to www.advancedbifurcation.com.
About EBC 2017
The European Bifurcation Club is an organization of European thought leaders in the treatment of coronary bifurcation lesions. The group holds an annual meeting to interact with the medical industry on the development of new concepts, processes and devices as well as to give scientific credibility to new clinical and technological projects.
Contact:
Advanced Birfurcation Systems
Charles Laverty
Chief Executive Officer
[email protected]
(949)432-4824


Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



